Improving survival in advanced melanoma patients: a trend analysis from 2013 to 2021-Reference-Cited by-同舟云学术

Improving survival in advanced melanoma patients: a trend analysis from 2013 to 2021

Published:2024-03 Issue: Volume:69 Page:102485
ISSN:2589-5370
Container-title:eClinicalMedicine
language:en
Short-container-title:eClinicalMedicine

Author:

van Not Olivier J.,van den Eertwegh Alfons J.M.,Haanen John B.,Blank Christian U.,Aarts Maureen J.B.,van Breeschoten Jesper^ORCID,van den Berkmortel Franchette W.P.J.,de Groot Jan-Willem B.,Hospers Geke A.P.,Ismail Rawa K.,Kapiteijn Ellen,Bloem Manja,De Meza Melissa M.,Piersma Djura,van Rijn Rozemarijn S.,Stevense-den Boer Marion A.M.,van der Veldt Astrid A.M.,Vreugdenhil Gerard,Boers-Sonderen Marye J.,Blokx Willeke A.M.,Wouters Michel W.J.M.,Suijkerbuijk Karijn P.M.^ORCID

Funder

ZonMw

Publisher

Elsevier BV

Reference29 articles.

1. Survival of patients with advanced metastatic melanoma: the impact of novel therapies;Ugurel;Eur J Cancer,2016

2. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma;Wolchok;Ann N Y Acad Sci,2013

3. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial;Hauschild;Lancet,2012

4. Pembrolizumab versus ipilimumab in advanced melanoma;Robert;N Engl J Med,2015

5. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial;Dummer;Lancet Oncol,2018

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. lnsights into Adjuvant Systemic Treatment Selection for Patients with Stage III Melanoma: Data from the Dutch Cancer Registry;Targeted Oncology;2024-08-24

2. Adverse Events in Anti-PD-1-Treated Adjuvant and First-Line Advanced Melanoma Patients;Cancers;2024-07-26